Literature DB >> 22457216

Targeting TNF receptors in rheumatoid arthritis.

Stephan Blüml1, Clemens Scheinecker, Josef S Smolen, Kurt Redlich.   

Abstract

Tumour necrosis factor (TNF) is a pro-inflammatory cytokine that signals through two distinct receptors, TNFR1 and TNFR2. TNF is essentially involved in the pathogenesis of various inflammatory and autoimmune diseases. Blocking TNF, in turn, has been proven to be highly effective in treating a variety of diseases. However, the role of its two receptors in these conditions is not very well understood. It is established that TNFR1 is mainly responsible for the detrimental effects of TNF. However, accumulating evidence suggests differential or even opposing effects of TNFR2 in the pathogenesis of a number of inflammatory and autoimmune conditions. In this review, we summarize the available data concerning biological and functional properties of the two TNF receptors and potential therapeutic consequences of these insights.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457216     DOI: 10.1093/intimm/dxs047

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  32 in total

1.  Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis?: Comment on Olson et al.: "Therapeutic Opportunities to Prevent Post-Traumatic Arthritis: Lessons From the Natural History of Arthritis After Articular Fracture".

Authors:  Jian-Lu Wei; John Buza; Chuan-Ju Liu
Journal:  J Orthop Res       Date:  2015-12-08       Impact factor: 3.494

2.  Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members.

Authors:  Julia T Warren; Christopher A Nelson; Corinne E Decker; Wei Zou; Daved H Fremont; Steven L Teitelbaum
Journal:  Sci Signal       Date:  2014-08-19       Impact factor: 8.192

3.  TNFRSF1B Is Associated with ANCA in IBD.

Authors:  Dalin Li; Mark S Silverberg; Talin Haritunians; Marla C Dubinsky; Carol Landers; Joanne M Stempak; Raquel Milgrom; Xiuqing Guo; Yii-Der Ida Chen; Jerome I Rotter; Kent D Taylor; Dermot P B McGovern; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

Review 4.  [Biologicals and small molecules for rheumatoid arthritis].

Authors:  Stephan Blüml
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

5.  Effectiveness of lentivirus-mediated RNA interference targeting mouse tumor necrosis factor α in vitro and in vivo.

Authors:  Jibo Wang; Yingjie Zhao; Miaomiao Xin; Lin Pan; Liqin Wang; Kun Yang
Journal:  Exp Ther Med       Date:  2017-12-11       Impact factor: 2.447

Review 6.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 7.  Cell-signaling therapy in rheumatoid arthritis.

Authors:  Edward Keystone; Marc D Cohen
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

8.  Dual neutralization of TNFR-2 and MMP-2 regulates the severity of S. aureus induced septic arthritis correlating alteration in the level of interferon gamma and interleukin-10 in terms of TNFR2 blocking.

Authors:  Sahin Sultana; Rajen Dey; Biswadev Bishayi
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 9.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

Review 10.  Mechanisms of tissue damage in arthritis.

Authors:  Stephan Blüml; Kurt Redlich; Josef S Smolen
Journal:  Semin Immunopathol       Date:  2014-09-12       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.